Jefferies on Divi's Labs | Brokerage reduced the pharma company's FY23/24 EPS estimates by 6/9 percent and cut the target price by 10 percent. It noted that the fourth-quarter numbers were flat.
Goldman Sachs on Divi's Labs | The brokerage firm maintained 'buy' with a target of 4,850 for the pharmaceutical company. However, it cut the FY 23/24e EPS estimates by 3-8 percent.
Motilal Oswal on Divi's Labs | The domestic brokerage maintained a 'buy' with a target of 4,480 as it noted that the pharma company delivered a better-than-expected FY22 Q4.
Credit Suisse on auto | It upgraded Ashok Leyland and Bajaj Auto to 'buy' from 'outperform' with a raised target price of Rs 178 per share and Rs 4,493 apiece respectively.
Morgan Stanley on Zomato | The brokerage firm maintained 'overweight' for the food delivery firm with a target of 135. It noted that the company is moving in the right direction, but needs consistent execution to meet the high expectations.(Edited by : Ajay Vaishnav)
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Delhi, Indore, Surat and Banswara — why these are the most challenging domains for Congress internally
May 4, 2024 1:53 PM
Congress nominee from Puri Lok Sabha seat withdraws, citing no funds from party
May 4, 2024 12:00 PM
Lok Sabha Polls '24 | Rahul Gandhi in Rae Bareli, why not Amethi
May 4, 2024 9:43 AM